Here are the key details to know:
1. DEXYCU is the first FDA-approved single dose, sustained release intracameral steroid for the treatment of postoperative inflammation.
2. The code, J1095, will become effective Jan. 1, 2019, and will replace the previously issued C-code for DEXYCU (C9034) that became effective Oct. 1, 2018.
3. EyePoint Pharmaceuticals still retains transitional pass-through status for DEXYCU from CMS for approximately three years.
More articles on coding, billing and collections:
5 steps ASCs can follow to improve ASC billing performance
Maximize your 2018 reimbursements: Know your health plans, know your market, and stay on top of trends
3 essential elements, benefits to launching a bundled payment program in ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
